Osiris Therapeutics Falls On Trail Results (NSPH, MODL, CNSL, ATPG, OSIR)
Nanosphere, Inc. (NASDAQ:NSPH) stock surged 20.63% to $3.04 after the company announced that the U.S. Food and Drug Administration has granted a de novo petition permitting marketing of its Gram-Positive Blood Culture Nucleic Acid Test or BC-GP on the automated sample-to-result Verigene System. The test will help fast detection of bacteria in bloodstream infections.
Additionally, the shares of the company was upgraded by research analysts at Jefferies Group from a “hold” rating to a “buy” rating in a report released today.
MModal Inc (NASDAQ:MODL) stock climbed 8.58% to $14.04 after the company, along with One Equity Partners announced that they have entered into a definitive agreement pursuant to which One Equity Partners, the private investment arm of JP Morgan Chase & Co., will acquire all of the outstanding shares of MModal for $14.00 per share in an all-cash transaction. The transaction is valued at approximately $1.1 billion.
Consolidated Communications Holdings Inc (NASDAQ:CNSL) stock surged 7.70% to $16.50 after the company announced that it has completed the previously announced acquisition of SureWest Communications, for approximately $324 million, exclusive of debt, based upon the closing price of the company’s common stock on June 29, 2012.
ATP Oil & Gas Corporation (NASDAQ:ATPG) shares climbed 4.99% to $4.21 after the company, along with the its wholly-owned subsidiary ATP East Med B.V. (“ATP East Med”) today announced success at the Shimshon well in the Levant Basin of offshore Israel. The Shimshon well encountered more than 62 feet (19 meters) of natural gas pay in the Bet Guvrin sands. The Shimshon well is in a water depth of 3,622 feet (1,104 meters) and was drilled to a subsea depth of 14,445 feet (4,403 meters).
Osiris Therapeutics, Inc. (NASDAQ:OSIR) shares declined 7.36% to $10.07 after the company announced interim one-year results from its groundbreaking clinical trial evaluating Prochymal for the treatment of patients experiencing first-time acute myocardial infarction. The trial is the study of allogeneic or off-the-shelf stem cells ever conducted in heart attack patients.